Antidepressive Agents, Second-Generation
"Antidepressive Agents, Second-Generation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
Descriptor ID |
D018687
|
MeSH Number(s) |
D27.505.954.427.700.122.050
|
Concept/Terms |
Antidepressive Agents, Second-Generation- Antidepressive Agents, Second-Generation
- Antidepressive Agents, Second Generation
- Antidepressive Drugs, Second-Generation
- Antidepressive Drugs, Second Generation
- Drugs, Second-Generation Antidepressive
- Second-Generation Antidepressive Drugs
- Atypical Antidepressants
- Second-Generation Antidepressive Agents
- Agents, Second-Generation Antidepressive
- Second Generation Antidepressive Agents
- Antidepressants, Atypical
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents, Second-Generation".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents, Second-Generation".
This graph shows the total number of publications written about "Antidepressive Agents, Second-Generation" by people in this website by year, and whether "Antidepressive Agents, Second-Generation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 0 | 1 | 1997 | 1 | 0 | 1 | 1999 | 0 | 1 | 1 | 2001 | 2 | 0 | 2 | 2004 | 2 | 0 | 2 | 2007 | 1 | 0 | 1 | 2010 | 1 | 0 | 1 | 2011 | 0 | 1 | 1 | 2012 | 1 | 1 | 2 | 2013 | 1 | 0 | 1 | 2014 | 2 | 0 | 2 | 2015 | 1 | 0 | 1 | 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antidepressive Agents, Second-Generation" by people in Profiles.
-
Rappaport LM, Russell JJ, Hedeker H, Pinard G, Bleau P, Moskowitz DS. Affect, interpersonal behaviour and interpersonal perception during open-label, uncontrolled paroxetine treatment of people with social anxiety disorder: a pilot study J Psychiatry Neurosci. 2018 11 01; 43(6):407-415.
-
Siddique J, Reiter JP, Brincks A, Gibbons RD, Crespi CM, Brown CH. Multiple imputation for harmonizing longitudinal non-commensurate measures in individual participant data meta-analysis. Stat Med. 2015 Nov 20; 34(26):3399-414.
-
Brent DA, Gibbons R. Initial dose of antidepressant and suicidal behavior in youth: start low, go slow. JAMA Intern Med. 2014 Jun; 174(6):909-11.
-
Mikami K, Jorge RE, Moser DJ, Arndt S, Jang M, Solodkin A, Small SL, Fonzetti P, Hegel MT, Robinson RG. Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy. J Neuropsychiatry Clin Neurosci. 2014; 26(4):323-8.
-
Mikami K, Jorge RE, Moser DJ, Arndt S, Jang M, Solodkin A, Small SL, Fonzetti P, Hegel MT, Robinson RG. Prevention of poststroke apathy using escitalopram or problem-solving therapy. Am J Geriatr Psychiatry. 2013 Sep; 21(9):855-62.
-
Abdala-Valencia H, Berdnikovs S, McCary CA, Urick D, Mahadevia R, Marchese ME, Swartz K, Wright L, Mutlu GM, Cook-Mills JM. Inhibition of allergic inflammation by supplementation with 5-hydroxytryptophan. Am J Physiol Lung Cell Mol Physiol. 2012 Oct 15; 303(8):L642-60.
-
McNutt MD, Liu S, Manatunga A, Royster EB, Raison CL, Woolwine BJ, Demetrashvili MF, Miller AH, Musselman DL. Neurobehavioral effects of interferon-a in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology. 2012 May; 37(6):1444-54.
-
Mitchell JE, Agras S, Crow S, Halmi K, Fairburn CG, Bryson S, Kraemer H. Stepped care and cognitive-behavioural therapy for bulimia nervosa: randomised trial. Br J Psychiatry. 2011 May; 198(5):391-7.
-
Jiao J, Nitzke AM, Doukas DG, Seiglie MP, Dulawa SC. Antidepressant response to chronic citalopram treatment in eight inbred mouse strains. Psychopharmacology (Berl). 2011 Feb; 213(2-3):509-20.
-
Owley T, Brune CW, Salt J, Walton L, Guter S, Ayuyao N, Gibbons RD, Leventhal BL, Cook EH. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 2010 Feb; 3(1):1-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|